Company Prevail Therapeutics Inc.
Equities
PRVL
US74140Y1010
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Franz Hefti
CEO | Chief Executive Officer | 76 | 18-02-28 |
Jeffrey Sevigny
CTO | Chief Tech/Sci/R&D Officer | 55 | 18-02-28 |
Emily Minkow
PRN | Corporate Officer/Principal | 41 | 18-10-31 |
Yong Dai
PRN | Corporate Officer/Principal | 53 | 19-01-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 34,248,033 | 29,795,530 ( 87.00 %) | 0 | 87.00 % |
Company contact information
Prevail Therapeutics, Inc.
430 East 29th Street Suite 1520
10016, New York
+
http://www.prevailtherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |